FPFrank Pistrosch

Frank Pistrosch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank Pistrosch has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Strategie zur strukturierten interdisziplinären Zusammenarbeit für Versorgung der Patienten mit Diabetes in Praxis und Klinik

    by Nikolaos Perakakis, Alexander Paliege, Norbert Weiss, Uwe Lindner, Frank Pistrosch, Peter Schwarz, Stefan R. Bornstein

    Diabetes mellitus ist eine der häufigsten Krankheiten weltweit [1]. In Deutschland leiden mehr als 7 Millionen Menschen an Diabetes, mit steigender Prävalenz [2]. Schätzungen zufolge werden 2040 ca. 11,5 Millionen Menschen in Deutschland betroffen sein [3]. Es konnten regionale Unterschiede in der Prävalenz des Typ-2-Diabetes mellitus (T2DM) beobachtet werden, wobei die höchste Prävalenz in den neuen Bundesländern (> 13 %) festgestellt wurde. Darüber hinaus ist die Prävalenz sowohl für bekannten und unerkannten Diabetes, als auch für das 5-Jahre-Diabetesrisiko in den unteren Bildungsschichten erhöht, was auf soziale Ungleichheiten in Deutschland hinweist [4]. Diabetes ist mit einem deutlich erhöhten Risiko für schwerwiegende Folge- und Begleiterkrankungen assoziiert und reduziert sowohl die Lebenserwartung als auch die Lebensqualität. Die häufigsten auftretenden Begleiterkrankungen sind Hypertonie, Dyslipidämie, Niereninsuffizienz (häufigste Ursache einer Dialyse), Polyneuropathie und kardiovaskuläre Erkrankungen [5], [6]. Menschen mit Diabetes haben ein bis zu 2,6-fach erhöhtes Risiko für einen frühzeitigen Tod und eine ca. 6 Jahre geringere Lebenserwartung im Vergleich zu Menschen ohne Diabetes. Erfreulicherweise sinken die Mortalitätsraten seit mehr als 20 Jahren stetig [7]. Die zunehmende Lebenserwartung könnte jedoch zur Vermehrung der diabetesassoziierten gesundheitlichen Einschränkungen führen. Daher ist eine kontinuierliche, gut koordinierte, evidenzbasierte medizinische Versorgung von großer Bedeutung. In der Diabetesversorgung sind ca. 4300 Diabetologen, 5000 Diabetesberater, 9000 Diabetesassistenten, 3500 Wundassistenten und ca. 300 stationäre Einrichtungen involviert. Zusätzlich betreut ein Hausarzt durchschnittlich ca. 100 Patienten mit Diabetes [8]. Trotz der sehr hohen und weiter steigenden Prävalenz werden sowohl die Behandlungskapazitäten, besonderes im stationären Setting, als auch klinische Lehrstühle in der Diabetologie und Endokrinologie abgebaut. Derzeit ist das Fach nur an 8 von 38 medizinischen Fakultäten in Deutschland repräsentiert. Diese Entwicklung hat erhebliche Konsequenz sowohl in der Ausbildung von Medizinstudenten als auch in der Weiterbildung von Fachärzten in der Diabetologie/Endokrinologie. Darüber hinaus besteht ein großer Mangel an spezialisiertem Pflegepersonal im Diabetesbereich. Der wichtigste Grund für dieses Paradox ist die inadäquate Vergütung nach DRG der Diabetesbehandlung. Diese Entwicklung hat erhebliche Konsequenzen sowohl in der Behandlung der Patienten als auch im Nachwuchs von qualifiziertem Fachpersonal. Im Rahmen der Diabetes-Surveillance in der vom Robert-Koch Institut (RKI) durchgeführten Studie „Krankheitswissen und Informationsbedarf – Diabetes mellitus“, wurde die Versorgungsqualität von Diabetespatienten in Deutschland nach deren eigener Einschätzung untersucht. Die Befragten gaben dabei eine mittelmäßige Qualität ihrer Versorgung an, wobei die Qualität mit zunehmendem Alter und höherer Bevölkerungszahl weiter abnahm [9]. Ein weiteres Problem sind die, durch Diabetes verursachten, hohen sozialen und ökonomischen Kosten. Die direkten Exzess-Kosten einer Person mit Diabetes sind doppelt so hoch wie die einer Person ohne Diabetes [10]. Der Großteil dieser Kosten steht mit den Folgeerkrankungen des Diabetes in Verbindung, was zum einen die Prävention von Diabetes, zum anderen den rechtzeitigen Beginn einer adäquaten Versorgung umso relevanter macht. Publication Date: 17 May 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers

    by Frank Pistrosch, Jan B. Matschke, Dorothea Schipp, Bernhard Schipp, Elena Henkel, Ingo Weigmann, Jan Sradnick, Stefan R. Bornstein, Andreas L. Birkenfeld, Markolf Hanefeld

    Aims/hypothesis: Individuals with type 2 diabetes mellitus and subclinical inflammation have stimulated coagulation, activated platelets and endothelial dysfunction. Recent studies with the direct factor Xa inhibitor rivaroxaban in combination with low-dose aspirin demonstrated a significant reduction of major cardiovascular events, especially in individuals with type 2 diabetes and proven cardiovascular disease. Therefore, we asked the question of whether treatment with rivaroxaban could influence endothelial function, arterial stiffness and platelet activation. Methods: We conducted a multi-centre, prospective, randomised, open-label trial in 179 participants with type 2 diabetes (duration 2–20 years), subclinical inflammation (high-sensitivity C-reactive protein 2–10 mg/l) and at least two traits of the metabolic syndrome to compare the effects of the direct factor Xa inhibitor rivaroxaban (5 mg twice daily) vs aspirin (100 mg every day) on endothelial function (assessed by forearm occlusion plethysmography), skin blood flow (assessed by laser-Doppler fluxmetry), arterial stiffness (assessed by pulse wave velocity) and serum biomarkers of endothelial function and inflammation. Furthermore, we investigated phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in platelets, the concentration of platelet-derived microparticles (PMPs) and the effects of isolated PMPs on HUVEC proliferation in vitro. Results: Rivaroxaban treatment for 20 weeks (n = 89) resulted in a significant improvement of post-ischaemic forearm blood flow (3.6 ± 4.7 vs 1.0 ± 5.2 ml/100 ml, p = 0.004), a numerically increased skin blood flow and reduced soluble P-Selectin plasma level vs aspirin. We did not find significant differences of arterial stiffness or further biomarkers. Neither rivaroxaban nor aspirin influenced VASP phosphorylation of platelets. The number of PMPs increased significantly with both rivaroxaban (365.2 ± 372.1 vs 237.4 ± 157.1 μl−1, p = 0.005) and aspirin (266.0 ± 212.7 vs 201.7 ± 162.7 μl−1, p = 0.021). PMPs of rivaroxaban-treated participants stimulated HUVEC proliferation in vitro compared with aspirin. Rivaroxaban was associated with a higher number of bleeding events. Conclusions/interpretation: Our findings indicate that the direct factor Xa inhibitor rivaroxaban improved endothelial function in participants with type 2 diabetes and subclinical inflammation but also increased the risk of bleeding. Trial registration: ClinicalTrials.gov NCT02164578. Funding: The study was supported by a research grant from Bayer Vital AG, Germany. Graphical


  • Top Cited Papers

    Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

    by Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén, et al.


  • Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD

    by Christina Pamporaki, Aleksander Prejbisz, Robert Małecki, Frank Pistrosch, Mirko Peitzsch, Steffen Bishoff, Petra Mueller, Iris Meyer, Doreen Reimann, Katarzyna Hanus, et al.


  • Open Access

    Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes

    by Markolf Hanefeld, Katrin Engelmann, Dieter Appelt, Dirk Sandner, Ingo Weigmann, Xenia Ganz, Frank Pistrosch, Carsta Köhler, Antje Gasparic, Andreas L. Birkenfeld

    Increased levels of systemic vascular endothelial growth factors (VEGFs) in patients with diabetes are associated with increased risk of microvessel disease. On the other hand, low VEGF levels after intravitreal antibody application may be associated with acute cardiovascular complications and treatment failure. Individual levels of systemic VEGF vary in a wide range depending on analytical methods and quality of diabetes control. So far only limited information exists on intraindividual fluctuations over longer periods and circadian rhythms. We analysed the intraindividual variance of VEGF-A, VEGF-C and placental growth factor (PLGF) in CTAD (citrate-theophylline-adenine-dipyridamol) plasma as well as VEGF-A in serum over a period of 6 months in patients with stable controlled type 2 diabetes (10 M, 10 F) and age and sex matched subjects with normal glucose tolerance (NGT). Furthermore, circadian levels of VEGFs were controlled hourly from 7:30 a.m. to 7:30 p.m. under standardized metabolic ward conditions. In addition, the relationship to metabolic, hormonal and inflammatory biomarkers was analyzed. VEGF-A, VEGF-C and PLGF remained stable in plasma and VEGF-A in serum over 6 months in both groups. No circadian change was observed in VEGF-A serum and plasma concentrations. A minor decrease of VEGF-C plasma levels was evident after 5 p.m. in both groups and a significant peak of PLGF concentrations occurred after lunch, which was more pronounced in T2DM. In multivariate analysis, only serum VEGF-A correlated to diabetes duration, whereas VEGF-C only correlated to HbA1c and fasting blood glucose. We did not observe significant intraindividual variances for VEGF-A in serum and VEGF-A, VEGF-C and PLGF in CTAD plasma over a period of 6 months. Taken together, a single morning measurement of systemic VEGF levels after 7:30 am appears to be a reliable parameter for the individual risk associated with abnormal VEGF concentrations in blood. Trial Registration: NCT02325271


  • Open Access

    Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

    by Markolf Hanefeld, Brian M. Frier, Frank Pistrosch

    Severe hypoglycemia is recognized to be one of the strongest predictors of macrovascular events, adverse clinical outcomes, and mortality in patients with type 2 diabetes. However, it is uncertain whether a direct pathophysiological link exists or whether hypoglycemia is primarily a marker of vulnerability to these events. Large clinical trials have reported an increased hazard ratio for all-cause mortality and cardiovascular events in patients with type 2 diabetes and severe hypoglycemia, but such an association has not been demonstrated in prospective trials of people with type 1 diabetes. Several cardiovascular effects occur during hypoglycemia either as a result of low blood glucose levels per se or through activation of the sympathoadrenal response: hemodynamic changes with an increase in cardiac work load and potential attenuation of myocardial perfusion, electrophysiological changes that may be arrhythmogenic, induction of a prothrombotic state, and release of inflammatory markers. Although the potential for a causal relationship has been demonstrated in mechanistic studies, the evidence from large prospective studies that hypoglycemia is a major causal contributor to cardiovascular events is limited to date. Other preexisting cardiovascular risk factors in addition to hypoglycemia may be the major link to the final cardiovascular event, but a low blood glucose level can trigger these events in patients with a high cardiovascular risk.


  • Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies

    by Frank Pistrosch, Markolf Hanefeld

    Severe hypoglycemia is recognized to be one of the strongest predictors of macrovascular events, adverse clinical outcomes, and mortality in patients with type 2 diabetes. Large clinical trials have reported an increased hazard ratio for all-cause mortality and cardiovascular events in patients with type 2 diabetes and severe hypoglycemia. However, these trials also reported an increased hypoglycemia-associated mortality rate in patients allocated to standard treatment by a factor of 1.5–2 despite a significant 50 % to 70 % lower incidence of hypoglycemia compared to the intensive treatment group. Although the potential for a causal relationship has been demonstrated in mechanistic studies, the evidence from large prospective studies suggest that other pre-existing cardiovascular risk factors in addition to hypoglycemia may be the major link to the final cardiovascular event, and that a low blood glucose level can trigger these events in patients with a high cardiovascular risk.


  • Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus

    by T. Klemm, S. Neumann, B. Trülzsch, F. Pistrosch, M. Hanefeld, R. Paschke

    Mitochondrial diabetes is one of the most common monogenetic forms of diabetes mellitus. However, variable prevalences have been reported by different investigators. Therefore, the aim of our study was to investigate the prevalence of the most prevalent mitochondrial DNA mutation at position 3243 (A → G) in german patients with a positive family history of maternally inherited diabetes mellitus and/or hearing loss. We screened 1460 patients with diabetes mellitus by a questionnaire and identified 122 patients with a positive family history of maternal diabetes mellitus. Seven of the 122 patients suffered from hearing loss in addition. An EDTA blood sample of each patient was examined by polymerase chain reaction followed by a digestion with Bsp120I. In addition all samples were further examined by denaturing gradient gel electrophoresis to increase the detection limit for heteroplasmy. Only one mt DNA mutation at position 3243 could be detected in the 122 patients. The detection limit of denaturing gradient gel electrophoresis (DGGE) for heteroplasmy was 3%. We detected one new polymorphism at position 3333 (C → T) of the mitochondrial genome (0.8% of the patients), and a known polymorphism at position 3197 (T → C) in 10.6% of the patients. We therefore conclude that the frequency of the A3243G mutation is much lower in the investigated study population, mostly originating from Saxonia, than in asian populations.